116 related articles for article (PubMed ID: 26637882)
41. HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies.
Lu S; Wang Z; Liu H; Hao X
Breast Cancer Res Treat; 2010 Dec; 124(3):771-8. PubMed ID: 20401632
[TBL] [Abstract][Full Text] [Related]
42. The Val allele of HER-2 codon 655 predicts the progression of oral squamous cell carcinoma.
Wu CH; Tu HF; Gong NR; Chen YW; Liu CJ; Kao SY
Oral Oncol; 2009 Jul; 45(7):579-83. PubMed ID: 18849186
[TBL] [Abstract][Full Text] [Related]
43. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.
Ishitobi M; Miyoshi Y; Ando A; Hasegawa S; Egawa C; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Apr; 9(4):1376-80. PubMed ID: 12684407
[TBL] [Abstract][Full Text] [Related]
44. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
Tas F
Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
[TBL] [Abstract][Full Text] [Related]
45. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis.
Zhang N; Huo Q; Wang X; Chen X; Long L; Guan X; Jiang L; Ma T; Hu W; Yang Q
Gene; 2014 Feb; 535(2):170-6. PubMed ID: 24316488
[TBL] [Abstract][Full Text] [Related]
46. Interleukin 7 receptor alpha Thr244Ile genetic polymorphism is associated with susceptibility and prognostic markers in breast cancer subgroups.
Vitiello GAF; Losi Guembarovski R; Amarante MK; Ceribelli JR; Carmelo ECB; Watanabe MAE
Cytokine; 2018 Mar; 103():121-126. PubMed ID: 28964592
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors.
Furrer D; Lemieux J; Côté MA; Provencher L; Laflamme C; Barabé F; Jacob S; Michaud A; Diorio C
Breast; 2016 Dec; 30():191-196. PubMed ID: 27788409
[TBL] [Abstract][Full Text] [Related]
48. HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma.
Kruszyna Ł; Lianeri M; Roszak A; Jagodziński PP
Clin Biochem; 2010 Apr; 43(6):545-8. PubMed ID: 20026098
[TBL] [Abstract][Full Text] [Related]
49. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.
Lemieux J; Diorio C; Côté MA; Provencher L; Barabé F; Jacob S; St-Pierre C; Demers E; Tremblay-Lemay R; Nadeau-Larochelle C; Michaud A; Laflamme C
Anticancer Res; 2013 Jun; 33(6):2569-76. PubMed ID: 23749910
[TBL] [Abstract][Full Text] [Related]
50.
Banin Hirata BK; Losi Guembarovski R; Vitiello GAF; Guembarovski AL; Brajão de Oliveira K; Watanabe MAE
Dis Markers; 2017; 2017():6359603. PubMed ID: 28713192
[No Abstract] [Full Text] [Related]
51. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim.
Rutter JL; Chatterjee N; Wacholder S; Struewing J
Epidemiology; 2003 Nov; 14(6):694-700. PubMed ID: 14569185
[TBL] [Abstract][Full Text] [Related]
52. Polymorphism and overexpression of HER2/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India.
Shanmughapriya S; Senthilkumar G; Arun S; Vinodhini K; Sudhakar S; Natarajaseenivasan K
Arch Gynecol Obstet; 2013 Dec; 288(6):1385-90. PubMed ID: 23722284
[TBL] [Abstract][Full Text] [Related]
53. Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients.
Ananiev J; Aleksandrova E; Skerleva D; Gulubova M; Chokoeva A; Lotti T; Wollina U; Tchernev G; Kontić M; Stojšić J
Wien Med Wochenschr; 2015 Aug; 165(15-16):315-21. PubMed ID: 26208475
[TBL] [Abstract][Full Text] [Related]
54. Ile/Ile homozygosity at codon 655 of HER2 in schwannoma.
Wang VC; Li JW; Suen JH; Chuang TC; Kao MC
Acta Neurol Taiwan; 2011 Dec; 20(4):243-8. PubMed ID: 22315174
[TBL] [Abstract][Full Text] [Related]
55. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
56. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
[TBL] [Abstract][Full Text] [Related]
57. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece.
Kalemi TG; Lambropoulos AF; Gueorguiev M; Chrisafi S; Papazisis KT; Kotsis A
Cancer Lett; 2005 May; 222(1):57-65. PubMed ID: 15837541
[TBL] [Abstract][Full Text] [Related]
58. Effects of HER2 genetic polymorphisms on its protein expression in breast cancer.
Su Y; Jiang Y; Sun S; Yin H; Shan M; Tao W; Ge X; Pang D
Cancer Epidemiol; 2015 Dec; 39(6):1123-7. PubMed ID: 26323365
[TBL] [Abstract][Full Text] [Related]
59. HER2 Ile655Val polymorphism is negatively associated with breast cancer susceptibility.
de Almeida FC; Banin Hirata BK; Ariza CB; Losi Guembarovski R; de Oliveira KB; Suzuki KM; Guembarovski AL; Oda JMM; Vitiello GAF; Watanabe MAE
J Clin Lab Anal; 2018 Jul; 32(6):e22406. PubMed ID: 29417620
[TBL] [Abstract][Full Text] [Related]
60. HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses.
Millikan RC; Hummer AJ; Wolff MS; Hishida A; Begg CB
Breast Cancer Res Treat; 2005 Feb; 89(3):309-12. PubMed ID: 15754131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
